Publications by authors named "B Milcent"
Preclinical models and clinical studies have shown that anti-CD20-based treatment has multifaceted consequences on T-cell immunity. We have performed a prospective study of peripheral T-cell compartment in FL patients, all exhibiting high tumor burden and receiving rituximab-chemotherapy-based regimen (R-CHOP). Before treatment, FL patients harbor low amounts of peripheral naive T cells, but high levels of CD4 T, CD4 T and CD8 T subsets and significant amounts of CD38 HLA-DR activated T cells.
View Article and Find Full Text PDFArticle Synopsis
- Preclinical and clinical studies indicate that cancer treatment with antitumor antibodies generates a specific immune response, particularly involving CD4 T cells.
- This research identifies 21 T cell epitopes derived from the human CD20 protein, which are restricted by various HLA types and can stimulate T cell activity in both healthy individuals and lymphoma patients.
- These identified CD20-derived peptides have potential as therapeutic agents to enhance or track T cell responses in patients receiving anti-CD20 treatments like rituximab.
Clinical responses to anti-tumor monoclonal antibody (mAb) treatment have been regarded for many years only as a consequence of the ability of mAbs to destroy tumor cells by innate immune effector mechanisms. More recently, it has also been shown that anti-tumor antibodies can induce a long-lasting anti-tumor adaptive immunity, likely responsible for durable clinical responses, a phenomenon that has been termed the vaccinal effect of antibodies. However, some of these anti-tumor antibodies are directed against molecules expressed both by tumor cells and normal immune cells, in particular lymphocytes, and, hence, can also strongly affect the host adaptive immunity.
View Article and Find Full Text PDF